{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:32:39Z","timestamp":1792513959143,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Primary cardiac angiosarcoma is a rare malignant soft-tissue sarcoma derived from vascular endothelial cells or lymphatic endothelial cells, with a high malignancy, poor prognosis, and a lack of effective medical therapy. This article reports on two patients with primary cardiac angiosarcoma who received first-line treatment with multi-targeted anti-angiogenic agent, anlotinib monotherapy. The treatment rapidly controlled pleural and pericardial effusion, significantly reduced the tumor, improved symptoms, and showed satisfactory recent efficacy. This indicates that anlotinib offers a new first-line treatment option for advanced primary cardiac angiosarcoma.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1363235","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T04:49:15Z","timestamp":1711082955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: Two cases of advanced primary cardiac angiosarcoma treated with anlotinib and a retrospective analysis of the literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Pan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/COC.0000000000000106","article-title":"Primary cardiac sarcoma: 25-year Cleveland clinic experience","volume":"39","author":"Randhawa","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jtcvs.2019.12.109","article-title":"Survival outcomes in patients with primary cardiac sarcoma in the United States","volume":"162","author":"Yin","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B3","first-page":"104","article-title":"Incidence, prognostic significance, and survival outcomes of primary cardiac sarcoma: an updated population-based retrospective study","volume":"25","author":"Hammami","year":"2021","journal-title":"Anatol J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11020074","article-title":"Primary cardiac sarcoma: clinical characteristics and prognostic factors over the past 2 decades","volume":"11","author":"Bangolo","year":"2023","journal-title":"Diseases"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102617","DOI":"10.1016\/j.ctrv.2023.102617","article-title":"Multimodality treatment of primary cardiac angiosarcoma: a systematic literature review","volume":"120","author":"Stergioula","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00383-013-3261-4","article-title":"Primary pediatric cardiac malignancies: the SEER experience","volume":"29","author":"Davis","year":"2013","journal-title":"Pediatr Surg Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.24875\/CIRU.18000306","article-title":"Soft tissue angiosarcoma of the breast in a patient with Klippel-Trenaunay-Weber syndrome","volume":"86","author":"Bugarin-Estrada","year":"2018","journal-title":"Cir Cir"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12032-016-0831-z","article-title":"Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma","volume":"33","author":"Ogata","year":"2016","journal-title":"Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French sarcoma group (GSF\/GETO)","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S0003-4975(99)00700-6","article-title":"Primary cardiac tumors: early and late results of surgical treatment in 91 patients","volume":"68","author":"Centofanti","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/s0828-282x(06)70247-1","article-title":"A 30-year analysis of cardiac neoplasms at autopsy","volume":"21","author":"Butany","year":"2005","journal-title":"Can J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.12659\/MSM.889875","article-title":"Primary cardiac angiosarcoma\u2014a review","volume":"20","author":"Patel","year":"2014","journal-title":"Med Sci Monit"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0167-5273(02)00136-5","article-title":"Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases","volume":"84","author":"Meng","year":"2002","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/cas.14793","article-title":"The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian sarcoma consortium","volume":"112","author":"Chen","year":"2021","journal-title":"Cancer Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European organisation for research and treatment of cancer soft tissue and bone sarcoma group trials","volume":"50","author":"Young","year":"2014","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1245\/s10434-012-2334-2","article-title":"Cardiac angiosarcoma management and outcomes: 20-year single-institution experience","volume":"19","author":"Look Hong","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ytab505","DOI":"10.1093\/ehjcr\/ytab505","article-title":"Coronary intervention for severe stenosis in the ostial right coronary artery with cardiac angiosarcoma: a case report","volume":"6","author":"Hirai","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"ytac025","DOI":"10.1093\/ehjcr\/ytac025","article-title":"Right atrium angiosarcoma with feeding vessels from right coronary artery: a case report","volume":"6","author":"Yeh","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e15290","DOI":"10.1097\/MD.0000000000015290","article-title":"The effect of ifosfamide, epirubicin, and recombinant human endostatin therapy on a cardiac angiosarcoma: a case report","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"B25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF In signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"596732","DOI":"10.3389\/fonc.2021.596732","article-title":"Efficacy of anlotinib for the treatment of angiosarcoma of the face and neck: a case report","volume":"11","author":"Ren","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-22-1903","article-title":"Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft-tissue sarcoma: an open-label, single-arm, phase II trial","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1363235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T04:49:18Z","timestamp":1711082958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1363235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2024.1363235"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1363235","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"article-number":"1363235"}}